A Preclinical Model of Sepsis-Induced Myopathy with Disuse in Mice
June 14th, 2024
This murine model combines a septic insult with hindlimb muscle disuse to recapitulate the bedridden feature of the typical septic patient. The model represents a significant departure from previous models to study muscle dysfunction in sepsis and is a reproducible approach to addressing therapeutic strategies to treat this condition.
Our research focuses on understanding the mechanisms behind sepsis induced myopathy. Current models overlook the disuse component, which is crucial for bad reading septic patients. We aim to integrate this aspect for a more accurate disease model.
We have significantly advanced the field by combining cecal ligation and puncture model with high limb suspension. This integrated approach allow us to study the systematic effect of sepsis and the impact of muscle disuse on sepsis induced myopathy, providing a more realistic model for understanding the disease progression and potential interventions. Our protocol combines cecal ligation and puncture with high limb suspension to replicate the clinical scenario of human sepsis more accurately in mice.
By simulating muscle atrophy and weakness seen in septic patients, our approach provides a comprehensive model for studying the interplay between sepsis and muscle function, allowing for more targeted investigations into therapeutic interventions.
Overview
This study presents a murine model that integrates a septic insult with hindlimb muscle disuse, effectively mimicking the bedridden condition of septic patients. This innovative approach offers a reproducible method for investigating muscle dysfunction in sepsis and evaluating potential therapeutic strategies.
Key Study Components
Area of Science
- Neuroscience
- Muscle Physiology
- Sepsis Research
Background
- Sepsis can lead to significant muscle dysfunction, known as sepsis-induced myopathy.
- Current models often neglect the impact of muscle disuse in septic patients.
- Understanding the combined effects of sepsis and muscle disuse is crucial for developing effective treatments.
- This study aims to enhance existing models by incorporating both factors.
Purpose of Study
- To investigate the mechanisms behind sepsis-induced myopathy.
- To create a more accurate model that reflects the clinical scenario of human sepsis.
- To assess the systematic effects of sepsis alongside muscle disuse.
Methods Used
- Combination of cecal ligation and puncture with hindlimb suspension.
- Use of murine models to replicate human sepsis conditions.
- Assessment of muscle function and systemic effects.
- Evaluation of potential therapeutic interventions.
Main Results
- The integrated model successfully replicates the clinical features of sepsis in mice.
- Findings highlight the significant impact of muscle disuse on sepsis-induced myopathy.
- This model provides a platform for testing therapeutic strategies.
- Results contribute to a better understanding of disease progression in septic patients.
Conclusions
- The new murine model is a valuable tool for studying sepsis and muscle dysfunction.
- Incorporating muscle disuse into sepsis research offers new insights.
- This approach may lead to improved therapeutic strategies for septic patients.
Frequently Asked Questions
Executive Industry Relevance
Sepsis-induced myopathy presents a significant translational challenge, as most preclinical models fail to capture the combined effects of systemic infection and muscle disuse seen in bedridden patients. This integrated mouse model enables more predictive evaluation of therapeutic strategies targeting muscle weakness and atrophy in sepsis survivors. By aligning preclinical conditions with clinical realities, the model enhances confidence in early-stage target validation and risk assessment for portfolio advancement.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of the mechanistic interplay between sepsis and muscle disuse in disease progression.
- Supports functional target validation for interventions aimed at mitigating muscle atrophy in septic conditions.
- Facilitates predictive de-risking by modeling clinically relevant phenotypes observed in human patients.
Screening & Assay Development
- Provides a validated in vivo platform for quantitative assessment of muscle function and morphology.
- Enables reproducible evaluation of candidate therapeutics targeting sepsis-induced muscle weakness.
- Supports assay standardization for downstream compound screening and comparative studies.
Translational & Preclinical Research
- Aligns preclinical endpoints with disease-relevant clinical outcomes in sepsis survivors.
- Improves translational continuity by modeling both systemic and disuse-driven muscle pathology.
- Informs risk-adjusted advancement decisions for therapeutic candidates targeting muscle dysfunction.
Pipeline & Workflow Integration
This model bridges early discovery and preclinical validation by enabling hypothesis testing on the combined effects of sepsis and disuse. It supports lead identification and mechanistic de-risking for muscle-targeted interventions in sepsis.
- Discovery Biology: Facilitates hypothesis-driven studies on the mechanisms underlying sepsis-induced myopathy with disuse.
- Screening: Provides a reproducible system for quantitative muscle function assays and therapeutic evaluation.
- Analytics: Delivers measurable outputs such as muscle strength and atrophy for robust statistical comparison.
- Translational Research: Ensures disease-relevant modeling for improved preclinical-to-clinical alignment.
- Enterprise Reuse: Establishes a reusable platform for ongoing evaluation of diverse therapeutic modalities targeting muscle dysfunction in sepsis.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in target validation for sepsis-induced myopathy.
- Operational Value: Enhances standardization, reproducibility, and scalability of preclinical muscle function studies.
- Strategic Value: Supports informed go/no-go decisions and capital-efficient portfolio management by modeling clinically relevant endpoints.
- Portfolio Impact: Enables risk-adjusted prioritization of therapeutic candidates addressing muscle weakness in sepsis survivors.
Implementation Considerations
- Requires expertise in murine surgical models and muscle physiology assessment.
- Demands access to facilities for cecal ligation and puncture, hindlimb suspension, and in vitro muscle mechanics analysis.
- Necessitates cross-team standardization of protocols for reproducibility across studies.
- May require adaptation for different mouse strains or disease contexts as supported by the protocol.
- Potential limitations include model complexity and the need for specialized animal care during suspension and recovery.
